An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: October 12, 2005
Last updated: November 1, 2011
Last verified: November 2011
To evaluate whether maintenance renal transplant patients on micophenolate mofetil (MMF) can be safely converted to EC-MPS, based on adverse events and acute rejection within 6 months after switching from MMF to a EC-MPS regimen.
Kidney Transplant Recipients
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
||An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients
Primary Outcome Measures:
- Adverse events and acute rejection within 6 months after switching from MMF to a EC-MPS regimen .
Secondary Outcome Measures:
- Pharmacokinetic profiles of MMF and EC-MPS.
- Patient and graft survival, graft function
| Estimated Enrollment:
| Study Start Date:
| Primary Completion Date:
||July 2005 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years to 80 Years
|Genders Eligible for Study:
- Males and females aged between 18 and 80 years.
- Recipients of first or secondary cadaveric, living related or unrelated donor kidney transplant at least 6 months after transplantation.
- Patients currently receiving CsA-ME with MMF , with or without corticosteroids as part of their immunosuppressive regimen for at least 3 months prior to Screening.
- Patients receiving MMF at reduced dose prior to study entry
- Patients in a stable condition in terms of graft function (serum creatinine not above 2.3 mg/dL (=204 µmol/L) at screening and at baseline, or not increased by more than 20% at baseline compared to values obtained at screening), no change of immunosuppressive regimen due to graft malfunction, and any known clinically significant physical and/or laboratory changes for at least 2 months prior to enrollment.
- Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to or at screening. Effective contraception must be used during the trial, and for 6 weeks following discontinuation of the study medication, even where there has been a history of infertility.
- Patients who are willing and able to participate in the full course of the study and from whom written informed consent has been obtained.
- Multi-organ patients (e.g., kidney and pancreas) or previous transplant with any other organ different from kidney (secondary kidney transplant is allowed)
- Evidence of graft rejection or treatment of acute rejection within two months prior to Screening.
- Patients with any known hypersensitivity to EC-MPS or other components of the formulation (e.g., lactose)
- Patients with thrombocytopenia (<75,000/mm3), with an absolute neutrophil count of <1,500/mm3 and/or leukocytopenia (<2,500/mm3), and/or hemoglobin <6.0 g/dL prior to enrollment.
- Patients who have received an investigational drug within two weeks prior to Screening (i.e., before Day -14 of run-in period).
- Patients with a history of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin.
- Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception
- Presence of clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus that would interfere with the appropriate conduct of the study.
- Known positive HIV and/or Hepatitis B surface antigen positive.
- Evidence of drug and/or alcohol abuse.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00239044
No publications provided
||Novartis ( Novartis Pharmaceuticals )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 12, 2005
||November 1, 2011
||Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Keywords provided by Novartis:
Kidney transplant recipients; Enteric-coated Mycophenolate sodium (EC-MPS)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 26, 2015
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs